A detailed history of Concord Wealth Partners transactions in Edwards Lifesciences Corp stock. As of the latest transaction made, Concord Wealth Partners holds 52 shares of EW stock, worth $3,854. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52
Previous 62 16.13%
Holding current value
$3,854
Previous $5,000 40.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$59.7 - $93.78 $597 - $937
-10 Reduced 16.13%
52 $3,000
Q1 2024

Apr 30, 2024

SELL
$72.54 - $95.56 $15,668 - $20,640
-216 Reduced 77.7%
62 $5,000
Q4 2023

Apr 30, 2024

SELL
$61.71 - $77.76 $3,579 - $4,510
-58 Reduced 17.26%
278 $21,000
Q4 2023

Feb 05, 2024

SELL
$61.71 - $77.76 $3,579 - $4,510
-58 Reduced 17.26%
278 $21,000
Q3 2023

Apr 30, 2024

BUY
$69.28 - $93.38 $4,018 - $5,416
58 Added 20.86%
336 $23,000
Q3 2023

Oct 25, 2023

SELL
$69.28 - $93.38 $1,732 - $2,334
-25 Reduced 6.93%
336 $23,000
Q2 2023

Aug 07, 2023

BUY
$81.41 - $94.33 $2,767 - $3,207
34 Added 10.4%
361 $34,000
Q1 2023

Apr 26, 2023

SELL
$74.26 - $84.51 $39,580 - $45,043
-533 Reduced 61.98%
327 $27,000
Q4 2022

Jan 27, 2023

BUY
$68.3 - $87.44 $58,738 - $75,198
860 New
860 $64,000
Q2 2022

Aug 04, 2022

BUY
$86.5 - $128.27 $91,949 - $136,351
1,063 Added 233.11%
1,519 $144,000
Q1 2022

Apr 20, 2022

SELL
$101.96 - $128.34 $2,447 - $3,080
-24 Reduced 5.0%
456 $54,000
Q4 2021

Jan 21, 2022

BUY
$106.37 - $130.68 $21,486 - $26,397
202 Added 72.66%
480 $62,000
Q3 2021

Nov 09, 2021

SELL
$102.91 - $122.75 $17,083 - $20,376
-166 Reduced 37.39%
278 $31,000
Q2 2021

Jul 29, 2021

SELL
$83.84 - $104.76 $167 - $209
-2 Reduced 0.45%
444 $46,000
Q1 2021

May 13, 2021

BUY
$78.68 - $90.67 $18,096 - $20,854
230 Added 106.48%
446 $37,000
Q4 2020

Feb 16, 2021

BUY
$71.69 - $91.23 $15,485 - $19,705
216 New
216 $20,000

Others Institutions Holding EW

About Edwards Lifesciences Corp


  • Ticker EW
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 618,259,968
  • Market Cap $45.8B
  • Description
  • Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair...
More about EW
Track This Portfolio

Track Concord Wealth Partners Portfolio

Follow Concord Wealth Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

News

Stay updated on Concord Wealth Partners with notifications on news.